JP2017524685A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524685A5
JP2017524685A5 JP2016576082A JP2016576082A JP2017524685A5 JP 2017524685 A5 JP2017524685 A5 JP 2017524685A5 JP 2016576082 A JP2016576082 A JP 2016576082A JP 2016576082 A JP2016576082 A JP 2016576082A JP 2017524685 A5 JP2017524685 A5 JP 2017524685A5
Authority
JP
Japan
Prior art keywords
active agent
additive
layer
use according
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016576082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524685A (ja
JP6895755B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/061109 external-priority patent/WO2015177209A1/en
Publication of JP2017524685A publication Critical patent/JP2017524685A/ja
Publication of JP2017524685A5 publication Critical patent/JP2017524685A5/ja
Application granted granted Critical
Publication of JP6895755B2 publication Critical patent/JP6895755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016576082A 2014-05-20 2015-05-20 経皮送達システムにおける活性薬剤の放出を調節するための方法 Active JP6895755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169026 2014-05-20
EP14169026.3 2014-05-20
PCT/EP2015/061109 WO2015177209A1 (en) 2014-05-20 2015-05-20 Method for adjusting the release of active agent in a transdermal delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210979A Division JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Publications (3)

Publication Number Publication Date
JP2017524685A JP2017524685A (ja) 2017-08-31
JP2017524685A5 true JP2017524685A5 (enExample) 2018-06-21
JP6895755B2 JP6895755B2 (ja) 2021-06-30

Family

ID=50735939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016576082A Active JP6895755B2 (ja) 2014-05-20 2015-05-20 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP2019210979A Pending JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019210979A Pending JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Country Status (6)

Country Link
US (2) US11426359B2 (enExample)
EP (1) EP3145503A1 (enExample)
JP (2) JP6895755B2 (enExample)
CN (1) CN106456567A (enExample)
CA (1) CA2948219C (enExample)
WO (1) WO2015177209A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2017073516A1 (ja) * 2015-10-26 2017-05-04 久光製薬株式会社 貼付剤
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) * 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
PL3854388T3 (pl) * 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
EP4046630A1 (en) * 2021-02-18 2022-08-24 LTS Lohmann Therapie-Systeme AG Tts-formulation with thc
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5032207A (en) 1988-03-04 1991-07-16 Noven Pharmaceuticals, Inc. One-step method for forming a pressure-sensitive adhesive transdermal drug device
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US4994278A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5300291A (en) 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
DK0474647T3 (da) 1990-03-28 1997-08-18 Noven Pharma Fremgangsmåde og indretning til frigivelse af lægemidler til huden
SG43349A1 (en) 1991-04-25 1997-10-17 Noven Pharma Method and apparatus for forming a transdermal drug device
US5387189A (en) 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
WO1999049582A2 (en) 1998-03-20 1999-09-30 Koninklijke Philips Electronics N.V. Receiver with a clock signal generator
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6757560B1 (en) 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6317630B1 (en) 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
ES2260021T3 (es) 1999-06-08 2006-11-01 Altea Therapeutics Corporation Aparatos para la microporacion de membranas biologicas utilizando dispositivos de interfaz de tejido de pelicula delgada, y su metodo.
MXPA02000118A (es) 1999-07-02 2003-02-27 Lohmann Therapie Syst Lts Sistema de microdepositos a base de polisiloxanos y solventes ambifilos.
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
HUP0303454A3 (en) 2001-04-02 2005-12-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
DE10118282A1 (de) 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
EP1344522A1 (en) 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
SI1256340T1 (en) 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
AU2002329763B2 (en) 2001-08-17 2007-11-08 Lavipharm Laboratories Inc. Composition and transdermal drug delivery device
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US6775570B2 (en) 2002-02-04 2004-08-10 Ceramatec, Inc. Iontophoretic treatment device
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1590823A4 (en) 2003-01-02 2007-05-30 Cymbet Corp BATTERY DRIVEN SOLID BODIES AND MANUFACTURING METHOD
US7603144B2 (en) 2003-01-02 2009-10-13 Cymbet Corporation Active wireless tagging system on peel and stick substrate
CN100512806C (zh) 2003-04-14 2009-07-15 Lts勒曼治疗系统股份公司 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂
JP2007522262A (ja) 2003-06-26 2007-08-09 シミックス・テクノロジーズ・インコーポレイテッド フォトレジストポリマー
EP1663179A1 (en) 2003-07-21 2006-06-07 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CA2567688C (en) 2004-05-28 2016-08-02 Jan De Geest Communication unit for a person's skin
JP2006178807A (ja) 2004-12-24 2006-07-06 Echigo Fudagami Kk Ｉｃシート製造装置及びｉｃシート製造方法
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102006054733A1 (de) 2006-11-21 2008-05-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
WO2009026139A1 (en) 2007-08-17 2009-02-26 Isis Biopolymer Llc Iontophoretic drug delivery system
CA2697709A1 (en) 2007-08-24 2009-03-05 Gerhard Kullertz Use of compounds derived from cycloheximide for treating or preventing, in particular, ischaemias and cardiopathies
EP2197426A2 (en) 2007-10-19 2010-06-23 Abbott GmbH & Co. KG Solid dispersion product containing n-aryl urea-based compound
WO2009068520A2 (en) 2007-11-28 2009-06-04 Schwarz Pharma Ag Polymorphic form of rotigotine
WO2009158120A2 (en) 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
JP2009297808A (ja) 2008-06-11 2009-12-24 Chiyoda Integre Co Ltd 粘着テープ製造方法及び粘着テープ製造装置
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
AR074047A1 (es) 2008-09-09 2010-12-22 Transcu Ltd Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos
AU2009302853B2 (en) 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
TW201043287A (en) 2009-05-08 2010-12-16 Isis Biopolymer Llc Iontophoretic device with improved counterelectrode
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
CN102665699A (zh) * 2009-12-22 2012-09-12 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
AU2011332187B2 (en) 2010-11-23 2016-03-03 Teva Pharmaceuticals International Gmbh User-activated self-contained co-packaged iontophoretic drug delivery system
WO2012084969A1 (en) * 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system

Similar Documents

Publication Publication Date Title
JP2017524685A5 (enExample)
JP7153010B2 (ja) 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2017515869A5 (enExample)
JP2013526572A5 (enExample)
HK1243942A1 (zh) 舒尼替尼制剂及其在治疗青光眼中的使用方法
JP2011529854A5 (enExample)
DK201600113U1 (da) Transdermalt, terapeutisk system til administration af rivastigmin
CN103561737A (zh) 含有罗匹尼罗的贴附剂及其包装体
RU2019121301A (ru) Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку
JP2014503523A5 (enExample)
HRP20201880T1 (hr) Transdermalni terapijski sustav namijenjen primjeni aktivne tvari
JP2005528413A5 (enExample)
JP2014506914A5 (enExample)
JP2017515872A5 (enExample)
HRP20191048T1 (hr) Transdermalni sustavi koji onemogućavaju zloupotrebu i pogrešnu upotrebu
JP5514815B2 (ja) 経皮吸収製剤
EP3160461A1 (en) Transdermal delivery system
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
ES2829807T3 (es) Sistema de administración transdérmica de fármacos que contiene donepezilo
JP2018537451A5 (enExample)
US9539201B2 (en) Selegiline transdermal system
JP6002055B2 (ja) 貼付剤
EP3302422A1 (en) Formulations for aripiprazole delivery transdermally
RU2015129081A (ru) Гелевые композиции
JP2021102573A (ja) クエン酸フェンタニル含有経皮吸収製剤